YOLFTbeta
Guizhou Sanli Pharmaceutical Co Ltd

Guizhou Sanli Pharmaceutical Co Ltd

603439 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

10.49CNY-0.41 (-3.76%)

Price History

Full chart

Market Stats

Previous Close10.90
Open10.91
Day Range10.43 – 10.95
52-Week Range9.51 – 17.46
Volume10.43M
Market Cap5.32B
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.46%
Beta0.99
50-Day Avg12.20
200-Day Avg12.29

About

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonifying, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. In addition, the company trades medicinal herbs. Guizhou Sanli Pharmaceutical Co.,Ltd was founded in 1995 and is based in Anshun, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Qianfan Zhang
  • Employees1.89K
  • HeadquartersXiayun Industrial Park, Anshun, China, 561000, China
  • Websitehttps://www.gz-sanli.com

Leadership

  • Mr. Qianfan ZhangGM, Vice Chairman · b. 1986
  • Mr. Jue Ben WangVice Chairman & Deputy GM · b. 1986
  • Ms. Ke GuoFinancial Director, Accounting Supervisor & Director · b. 1987
  • Mr. Yi WangDeputy GM & Director · b. 1988
  • Mr. Yuan YuDeputy General Manager · b. 1982
  • Mr. Zhiyu YangDeputy General Manager · b. 1986
  • Mr. Li DengDeputy General Manager · b. 1985
  • Mr. Zhan Biao LuoDeputy General Manager · b. 1978
  • Ms. Jing LongManager of Human Resources Department · b. 1985

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue159.33M266.88M359.04M514.61M638.33M722.35M883.78M630.22M938.97M1.20B1.63B2.14B1.70B
Growth (%)-+67.50%+34.53%+43.33%+24.04%+13.16%+22.35%-28.69%+48.99%+27.94%+36.10%+31.16%-20.59%
Cost of Revenue60.72M101.49M135.65M179.91M214.02M249.77M298.76M208.98M277.07M339.52M437.99M652.98M511.49M
Gross Profit98.61M165.38M223.40M334.69M424.31M472.57M585.03M421.25M661.89M861.80M1.20B1.49B1.19B
Gross Margin61.89%61.97%62.22%65.04%66.47%65.42%66.20%66.84%70.49%71.74%73.21%69.55%69.96%
Operating Expense81.80M133.14M172.24M268.08M336.78M372.80M430.43M308.98M482.70M636.25M861.16M1.17B992.66M
Operating Income16.81M32.25M51.16M66.61M87.53M99.78M154.60M112.27M179.19M225.55M335.83M326.25M198.70M
Operating Margin10.55%12.08%14.25%12.94%13.71%13.81%17.49%17.81%19.08%18.78%20.54%15.21%11.67%
EBITDA25.75M38.49M64.23M94.28M110.83M138.02M163.56M120.21M196.19M243.68M374.61M413.63M152.90M
EBITDA Margin16.16%14.42%17.89%18.32%17.36%19.11%18.51%19.07%20.89%20.28%22.91%19.29%8.98%
Net Income19.37M28.99M52.61M74.88M87.63M110.48M133.08M93.95M152.28M201.28M292.70M274.03M46.25M
Net Income Margin12.16%10.86%14.65%14.55%13.73%15.29%15.06%14.91%16.22%16.76%17.90%12.78%2.72%
R&D37.35K132.90K344.38K5.62M2.70M6.86M3.51M5.63M7.68M17.86M30.61M46.50M27.91M
R&D as % of Total Revenue0.02%0.05%0.10%1.09%0.42%0.95%0.40%0.89%0.82%1.49%1.87%2.17%1.64%
Interest Expense1.18M2.37M628.06K30.55K44.76K273.45K227.62K2.23M8.36M5.30M4.16M14.65M11.07M
Interest Expense % of Total Revenue0.74%0.89%0.17%0.01%0.01%0.04%0.03%0.35%0.89%0.44%0.25%0.68%0.65%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets199.62M248.58M302.67M518.02M565.43M576.70M730.81M1.26B1.40B1.82B2.92B3.19B2.85B
Total Liabilities130.52M139.67M86.14M87.44M92.07M58.69M79.72M276.91M372.93M578.40M1.21B1.60B1.34B
Total Equity69.09M108.92M216.53M430.59M473.36M518.02M651.10M981.89M1.03B1.24B1.47B1.53B1.45B
Cash28.94M16.69M18.68M177.28M180.46M131.43M239.61M450.05M544.22M570.88M571.37M474.85M389.42M
Total Debt31.00M60.60M-----200.00M200.00M205.67M609.96M561.03M-
Net Debt2.06M43.91M-18.68M-177.28M-180.46M-131.43M-239.61M-250.05M-344.22M-365.21M38.59M86.19M308.97M

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow30.09M563.46K33.28M35.10M57.47M75.35M116.24M63.25M155.04M293.29M276.70M107.07M164.58M
Investing Cash Flow-8.76M-50.87M-24.78M-14.97M-9.19M-47.59M-6.09M-292.81M20.59M-266.56M-613.78M-103.00M-
Financing Cash Flow1.82M38.06M-6.20M138.47M-45.09M-76.78M-1.96M440.00M-81.46M-124.81K337.63M-100.60M-
Capital Expenditure8.77M26.29M50.53M12.36M7.17M1.78M8.01M51.71M26.08M119.91M108.73M45.20M25.84M
Free Cash Flow21.32M-25.73M-17.25M22.74M50.29M73.56M108.23M11.54M128.96M173.38M167.97M61.87M138.74M
Dividends Paid1.18M2.37M604.29K64.09M44.86M70.38M110.21M2.62M101.83M8.92M40.99M104.04M161.44M
FCF to OCF70.86%-4565.69%-51.83%64.79%87.52%97.63%93.11%18.25%83.18%59.12%60.70%57.79%84.30%
Dividend Paid to FCF5.55%-9.20%-3.50%281.83%89.20%95.68%101.83%22.72%78.96%5.15%24.40%168.15%116.37%

Earnings

Report DateJun 30, 2020Sep 30, 2020Dec 31, 2020Apr 28, 2021Aug 17, 2021Oct 29, 2021Dec 31, 2021Apr 21, 2022Aug 26, 2022Oct 28, 2022Dec 31, 2022Apr 14, 2023
EPS Estimate------------
EPS Actual0.050.010.110.060.110.100.100.060.100.100.240.23
Surprise------------
Timing---Pre-marketPre-marketAfter-hours-Pre-marketAfter-hoursPre-market-Pre-market

Key Statistics & Ratios

Market Cap5.32B
Enterprise Value5.93B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.41
Price / Book3.82
EPS0.00
Book Value3.63
Revenue (TTM)1.56B
Gross Profit (TTM)1.11B
EBITDA208.32M
Profit Margin0.02%
Operating Margin-6.12%
Return on Equity0.04%
Return on Assets3.17%
Shares Outstanding403.84M
Shares Float181.55M
Beta0.99
Dividend Yield0.46%
Dividend Rate0.06
Payout Ratio283.33%

Dividends

20231×
0.10Jun 1, 2023
20211×
0.25Jun 7, 2021